Publications & Posters – 2023

Subscribe to our updates
  • All
  • HMBD-001
  • HMBD-002
  • HMBD-011
  • HMBD-501
  • Posters
Posters

2 November, 2023

ESMO 2023: A CRUK phase I/IIA, first in human dose‐escalation and expansion trial of HMBD‐001 (an anti‐HER3 antibody) in patients with advanced HER3 positive solid tumours

Posters

11 September, 2023

WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

Posters

4 June, 2023

ASCO 2023: A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

Posters

18 May, 2023

AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

Posters

18 April, 2023

AACR 2023: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker selected pre-clinical models of squamous cell carcinomas

Posters

18 April, 2023

AACR 2023: HMBD-501 – a novel Fc engineered, exatecan-based next-generation HER3-targeting Antibody-Drug Conjugate (ADC) shows robust tolerability and efficacy in pre-clinical solid tumor models

Load more
All Years 2025 2024 2023 2022 2021 2020 2019 2018 2017